Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2022-12-12 / Front Immunol 2022;13:1080947Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-04 / Cancer Med 2022 Dec;Immunotherapy for the treatment of pediatric brain tumors: a narrative review
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2022-12-01 / Transl Pediatr 2022 Dec;11(12):2040-2056Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
/in International Publications, Newcastle Disease Virus /von 2022-11-26 / J Clin Med 2022 Nov;11(23)Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)Commentary on „Systematic review about complementary medical hyperthermia in oncology“ by Liebl et al
/in Hyperthermia, International Publications /von 2022-10-14 / Clin Exp Med 2022 Nov;22(4):667-672Cellular Immunotherapy for Medulloblastoma
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2022-10-11 / Neuro Oncol 2022 Oct;Immunogenic Cell Death Role in Urothelial Cancer Therapy
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-67133-Dimensional coculture of breast cancer cell lines with adipose tissue-Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection labeling technology
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2022-09-12 / Front Mol Biosci 2022;9:754100
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives